Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Ansaizhu (pertuzumab biosimilar)
i
Other names:
QL1209, QL 1209, QL-1209
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Qilu Pharma
Drug class:
HER2 dimerization inhibitor
Related drugs:
‹
pertuzumab (102)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
HS627 (pertuzumab biosimilar) (0)
P013 (pertuzumab biosimilar) (0)
Pertuvia (pertuzumab biosimilar) (0)
pertuzumab (102)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
(0)
(0)
(0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
HR negative
HER2 Positive Breast Cancer
HR negative
HER2 Positive Breast Cancer
QL1209 (pertuzumab biosimilar)
Sensitive: B - Late Trials
QL1209 (pertuzumab biosimilar)
Sensitive
:
B
QL1209 (pertuzumab biosimilar)
Sensitive: B - Late Trials
QL1209 (pertuzumab biosimilar)
Sensitive
:
B
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.